e-therapeutics PLC Chief executive Ali Mortazavi joins Proactive London after the recent launch of trading on the OTCQX Best Market under the ticker symbol ETXPF. He says this platform would help broaden the shareholder base.
He says their computational biology and RNAi therapeutics platforms are particularly suited to a global audience and they look forward to sharing the Company’s equity story with an international audience.
He also explains the progress on its RNAi Platform with results from characterisation benchmarking studies now successfully completed. The research demonstrated e-Therapeutics’ approach was equivalent in performance to leading competitor programmes showing 'deep and durable target gene knock-down'.